The Worldwide Hepatitis C Testing Industry is Projected to Reach $2.2 Billion by 2031 at a 5.3% CAGR

News provided by

Jan 24, 2023, 13:50 ET

DUBLIN, Jan. 24, 2023 /PRNewswire/ -- The "Hepatitis C Testing Market By Technique, By Test, By End User: Global Opportunity Analysis and Industry Forecast, 2021-2031" report has been added to ResearchAndMarkets.com's offering.

The global hepatitis C testing market was valued at $1,329.0 million in 2021, and is projected to reach $2,248.2 million by 2031, registering a CAGR of 5.3% from 2022 to 2031.

Hepatitis C is a viral infection that causes liver inflammation, sometimes leading to serious liver damage. The hepatitis C virus (HCV) spreads through contaminated blood. The hepatitis C can be diagnosed with antibody test, genotype test, and viral load test.

The increasing rate of hepatitis C and rise in awareness about hepatitis C drives the growth of market. For instance, according to a report of World Health Organization (WHO) published on June 2022, globally, an estimated 58 million people have chronic hepatitis C virus infection, with about 1.5 million new infections occurring per year. An estimated 3.2 million adolescents and children have the chronic hepatitis C infection. Thus, increase in prevalence of hepatitis C globally boosts the growth of the market.

In addition, factors such as increase in blood donation and rise in blood transfusion rate foster the growth of the market. The blood transfusion is a leading cause of hepatitis C virus transmission.

For instance, as per the report of World Health Organization (WHO) published on May 2022, about 118.54 million blood donations are made worldwide. 40% of these are collected in high-income countries. The World Health Organization (WHO) recommends that all blood donations should be screened for infections prior to use. Screening for HIV, hepatitis B, hepatitis C, and syphilis should be mandatory.

Moreover, increase in R&D activities for development of advanced hepatitis C testing such as immunoassay & polymerase chain reaction (PCR), rise in the U.S. food & drug administration (FDA) approvals and novel product launch in the market by key players boost the market growth.

For instance, in December 2020, Transasia Bio-Medicals, a leading Indian diagnostic company, announced the launch of India's first, high sensitivity testing kit for hepatitis C virus. Based on the latest method, the ErbaLisa HCV Gen 4 Ag+Ab kit, is India's first and only indigenously developed 4th gen ELISA kit and has been evaluated by the National Institute of Biologicals (NIB). Furthermore, advancements in hepatitis C diagnosis further contribute in market growth. However, the high cost of hepatitis C testing may hinder the growth of market.

The hepatitis C testing market is segmented on the basis of technique, test, end user, and region. By technique, market is fragmented into immunoassay, polymerase chain reaction (PCR), and others. The polymerase chain reaction (PCR) segment is further classified into real time PCR, and other PCR.

Depending on test, the market is classified into antibody test, genotype tests, and viral load test. On the basis of end user, the market is categorized into hospital & diagnostic laboratory, blood banks, and others. By region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The major companies profiled in the report include Abbott Laboratories, BIO-RAD laboratories Inc, Cosara Diagnostics Pvt Ltd, Illumina Inc, Meril Life Sciences Pvt. Ltd., Molbio Diagnostics Pvt. Ltd., PerkinElmer, Qiagen N.V., Thermo Fisher Scientific Inc, and Trivitron Healthcare.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the hepatitis c testing market analysis from 2021 to 2031 to identify the prevailing hepatitis c testing market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the hepatitis c testing market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global hepatitis c testing market trends, key players, market segments, application areas, and market growth strategies.

Key Topics Covered:

CHAPTER 1: INTRODUCTION

CHAPTER 2: EXECUTIVE SUMMARY

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.3. Porter's five forces analysis
3.4. Top player positioning
3.5. Market dynamics
3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities
3.6. COVID-19 Impact Analysis on the market

CHAPTER 4: HEPATITIS C TESTING MARKET, BY TECHNIQUE

4.1 Overview
4.1.1 Market size and forecast
4.2 Immunoassay
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.3 PCR
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
4.3.4 PCR Hepatitis C Testing Market by Type
4.3.4.1 Real time PCR Market size and forecast, by region
4.3.4.2 Other PCR Market size and forecast, by region
4.4 Other techniques
4.4.1 Key market trends, growth factors and opportunities
4.4.2 Market size and forecast, by region
4.4.3 Market analysis by country

CHAPTER 5: HEPATITIS C TESTING MARKET, BY TEST

5.1 Overview
5.1.1 Market size and forecast
5.2 Antibody test
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market analysis by country
5.3 Genotype tests
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market analysis by country
5.4 Viral load test
5.4.1 Key market trends, growth factors and opportunities
5.4.2 Market size and forecast, by region
5.4.3 Market analysis by country

CHAPTER 6: HEPATITIS C TESTING MARKET, BY END USER

6.1 Overview
6.1.1 Market size and forecast
6.2 Hospital and diagnostic laboratory
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market analysis by country
6.3 Blood banks
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market analysis by country
6.4 Other end users
6.4.1 Key market trends, growth factors and opportunities
6.4.2 Market size and forecast, by region
6.4.3 Market analysis by country

CHAPTER 7: HEPATITIS C TESTING MARKET, BY REGION

CHAPTER 8: COMPANY LANDSCAPE

8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments

CHAPTER 9: COMPANY PROFILES

9.1 Abbott Laboratories
9.1.1 Company overview
9.1.2 Company snapshot
9.1.3 Operating business segments
9.1.4 Product portfolio
9.1.5 Business performance
9.1.6 Key strategic moves and developments
9.2 BIO-RAD laboratories Inc
9.2.1 Company overview
9.2.2 Company snapshot
9.2.3 Operating business segments
9.2.4 Product portfolio
9.2.5 Business performance
9.2.6 Key strategic moves and developments
9.3 Cosara Diagnostics Pvt Ltd
9.3.1 Company overview
9.3.2 Company snapshot
9.3.3 Operating business segments
9.3.4 Product portfolio
9.3.5 Business performance
9.3.6 Key strategic moves and developments
9.4 Illumina Inc
9.4.1 Company overview
9.4.2 Company snapshot
9.4.3 Operating business segments
9.4.4 Product portfolio
9.4.5 Business performance
9.4.6 Key strategic moves and developments
9.5 Meril Life Sciences Pvt. Ltd.
9.5.1 Company overview
9.5.2 Company snapshot
9.5.3 Operating business segments
9.5.4 Product portfolio
9.5.5 Business performance
9.5.6 Key strategic moves and developments
9.6 Molbio Diagnostics Pvt. Ltd.
9.6.1 Company overview
9.6.2 Company snapshot
9.6.3 Operating business segments
9.6.4 Product portfolio
9.6.5 Business performance
9.6.6 Key strategic moves and developments
9.7 PerkinElmer
9.7.1 Company overview
9.7.2 Company snapshot
9.7.3 Operating business segments
9.7.4 Product portfolio
9.7.5 Business performance
9.7.6 Key strategic moves and developments
9.8 Qiagen N. V.
9.8.1 Company overview
9.8.2 Company snapshot
9.8.3 Operating business segments
9.8.4 Product portfolio
9.8.5 Business performance
9.8.6 Key strategic moves and developments
9.9 Thermo Fisher Scientific Inc
9.9.1 Company overview
9.9.2 Company snapshot
9.9.3 Operating business segments
9.9.4 Product portfolio
9.9.5 Business performance
9.9.6 Key strategic moves and developments
9.10 Trivitron Healthcare
9.10.1 Company overview
9.10.2 Company snapshot
9.10.3 Operating business segments
9.10.4 Product portfolio
9.10.5 Business performance
9.10.6 Key strategic moves and developments